Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosliciguat for pulmonary hypertension associated with interstitial lung disease
NL-OMON59093Phase 2Active, not recruiting
- Sponsor
- Pulmovant
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of mosliciguat, sponsored by Pulmovant. Started Mar 2025; status: active, not recruiting.
02
Drugs
mosliciguat
Beyond the preview
Go deeper on NL-OMON59093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59093.